AMJ published new Phase 3 data showing a multi-selective RAS inhibitor extended survival across major KRAS variants with fewer discontinuations than chemotherapy.

American Medical Journal (AMJ), was founded in 2024 building on the success of our partner publisher EMJ, established in 2012. AMJ was launched to better meet the changing needs of healthcare professionals within the United States. The American Medical Journal delivers high-quality, tailored content across six key therapy areas designed to support and enhance clinical practice for U.S. audiences. Our content builds trust between healthcare professionals and Pharma, to help them continuously improve together. At the core of our content community is a portfolio of peer-reviewed, open-access journals, which are complemented by alternative formats such as interactive content, podcasts, webinars, videos, and infographics. These provide an essential resource for senior medical professionals today and the brilliant new minds of tomorrow. We have built our incredible team by recruiting on values. We stay true to these values in everything we do, as we remain steadfast in our goal to create Gold Medal Winners. For trusted partners who share our vision, we invite you to get in touch and join us on our journey. Join our mailing list for FREE to receive the latest news and insights direct to your inbox: https://www.emjreviews.com/en-us/amj/mailing-list/